GlassScriptPhysician profile
Maryam Ghiassi
NPI 1346773934
$10,181.71
in general payments reported to CMS, 2019-2025
15 companies · $4,064 in 2025
The $4,064 reported for 2025 was more than what 87% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $164 · 2023: $558 · 2024: $5,279 · 2025: $4,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,139 · Food and Beverage: $3,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,139.25 |
| Food and Beverage | $3,761.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $3,914.87 | 2024-2025 | Dextenza |
| Genentech USA, INC. | $2,587.65 | 2022-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $1,192.88 | 2023-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $400.37 | 2023-2025 | Eylea Hd |
| Regeneron Pharmaceuticals, INC. | $393.29 | 2023-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $389.04 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $345.72 | 2024 | |
| Genentech, INC. | $297.29 | 2024-2025 | Vabysmo |
| Mallinckrodt Hospital Products INC. | $163.72 | 2023-2024 | Acthar |
| Amgen INC. | $152.08 | 2025 | Pavblu |
| Abbvie INC. | $145.21 | 2024-2025 | |
| Dutch Ophthalmic, USA | $117.59 | 2021 | |
| Ani Pharmaceuticals, INC. | $32.19 | 2025 | Iluvien |
| Alcon Vision LLC | $30.96 | 2022 | |
| Biogen, INC. | $18.85 | 2024 | Byooviz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Ghiassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.